Lung Cancer
Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Lung Cancer Patients
Published in Medical Verdicts and Law Weekly, July 26th, 2007
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, announced that it has submitted a clinical protocol with the Drug Controller General of India (DCGI) for a Phase II trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC). The multi-center trial is expected to begin enrolling patients once the protocol regulatory review is completed.
The trial has a two-stage design. Up to 21 NSCLC patients will be enrolled initially and the study will be expanded up to a total of 49 patients if...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- Allsup Inc.
Allsup Examines Impact of Social Security Taxes on Disabled and their Families - American Council of Life Insurers
ACLI Annual Conference Will Bring Life Insurance Industry Leaders to Washington, D.C. This Fall - American Life League
Law Evicts Planned Parenthood From Schools; a Noteworthy Victory for Parents in Missouri - Amistaff Healthcare Technology, Inc.
Amistaff Healthcare Technology, Inc. Announces a New Exam Validation Process to Improve the Quality of Patient Care - Antares Pharma
Antares Pharma Announces Closing of $16 Million Private Placement - AuthorHouse
'Murder Without Death': Small-Town Doctor Narrates His Fight Against Corruption - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
